The study is enrolling children from 6 to 11 years of age who have symptoms of inattention or hyperactivity and have an Autism Spectrum Disorder. The study involves the use of a medication called Daytrana (methylphenidate transdermal system) approved by the Food and Drug Administration (FDA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Daytrana is a patch that is worn on the skin, similar to a band-aid and has the ability to control ADHD signs and symptoms such as inability to:
- Pay attention
- Sit still
- Complete tasks
- Wait his/her turn
- Think before acting
- Follow through on instructions
Children who qualify to participate in this study will receive assessments by a medical doctor, medication and a small amount of money to cover some expenses for approximately 8 weeks at no charge.
To learn more about the study, contact Lora Tusing at 405-271-5700 ext. 45167
No comments:
Post a Comment